Stock KYMR KYMERA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Kymera Therapeutics, Inc.

Equities

KYMR

US5015751044

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-05-03 EDT 		5-day change 1st Jan Change
37.4 USD +3.03% Intraday chart for Kymera Therapeutics, Inc. +12.14% +46.90%
05-03 Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53 MT
05-02 Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oppenheimer Adjusts Kymera Therapeutics Price Target to $52 From $53
MT
Kymera Therapeutics Q1 Net Loss Narrows, Collaboration Revenue Rises
MT
Kymera Therapeutics : Corporate Presentation, May 2024
PU
Transcript : Kymera Therapeutics, Inc., Q1 2024 Earnings Call, May 02, 2024
Kymera Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
GL
Kymera Therapeutics, Inc. Provides Business Highlights and Updates on Its Pipeline of Protein Degraders
CI
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
GL
Oppenheimer Starts Kymera Therapeutics With Outperform Rating, $53 Price Target
MT
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
GL
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
AQ
Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting
CI
Kymera Therapeutics, Inc. Appoints Felix J. Baker to the Board
CI
Kymera Therapeutics Insider Sold Shares Worth $14,912,376, According to a Recent SEC Filing
MT
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
AQ
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
GL
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting
CI
Truist Ups Price Target on Kymera Therapeutics to $54 From $41, Keeps Buy Rating
MT
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
GL
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KYMR Stock
  4. News Kymera Therapeutics, Inc.